Rachel E Sayles, M.S.CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 565 Sayles St, Oneida, NY 13421 Phone: 315-363-2550 |
Bernadette Chapman, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 701 Lenox Ave, Oneida, NY 13421 Phone: 315-363-3397 |
Mrs. Kimberly Rae Bush, MS CCC SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 588 Broad Street, Oneida, NY 13421 Phone: 315-363-9281 Fax: 315-363-9286 |
Laurie J. Mutz Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 337 Broad St, Oneida, NY 13421 Phone: 315-363-1840 |
Mary Martin Domes, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 701 Lenox Ave, Oneida, NY 13421 Phone: 315-363-3397 |
News Archive
The Translational Genomics Research Institute (TGen) recently honored two significant Arizona philanthropists at their annual Founders Dinner for their support of TGen's research into brain, colon and prostate cancer. The event took place March 28 in Scottsdale.
Researchers at the University of Las Palmas de Gran Canaria (Spain) have analysed more than 60 brands of cheese commonly available in supermarkets. The concentration of organochloride contaminants in the majority of the samples was lower than levels set by European legislation, but in a few cases it was higher.
There are concerns regarding breast implants and the association with cancer. UP to 30,000 French women and perhaps tens of thousands more around the world may need to have defective breast implants removed after several suspicious cancer cases. The final decision on recall of the implants, produced by the Poly Implant Prothese (PIP) company will be made by the end of the week, after a report from France's National Cancer Institute on December 23.
Despite concerns that have been expressed about possible health risks from high intake of vitamin E, a new review concludes that biological mechanisms exist to routinely eliminate excess levels of the vitamin, and they make it almost impossible to take a harmful amount.
Chemokine Therapeutics has announced that it has been granted U.S. Patent No. 6,875,738 relating to the use of its anti-cancer compound, CTCE-9908, in the treatment of cancer and inhibition of angiogenesis. CTCE-9908 is designed to block CXCR4, a receptor found on the surface of cancer cells.
› Verified 1 days ago